Zacks Research Weighs in on Editas Medicine, Inc.'s Q3 2025 Earnings (NASDAQ:EDIT)

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for shares of Editas Medicine in a research note issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now expects that the company will post earnings per share of ($0.74) for the quarter, up from their previous forecast of ($0.75). The consensus estimate for Editas Medicine's current full-year earnings is ($2.61) per share. Zacks Research also issued estimates for Editas Medicine's Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.53) EPS.

Other equities research analysts have also issued reports about the company. JPMorgan Chase & Co. lifted their target price on Editas Medicine from $8.00 to $9.00 and gave the company a "neutral" rating in a research report on Tuesday, February 27th. Citigroup lifted their target price on Editas Medicine from $11.00 to $16.00 and gave the company a "buy" rating in a research report on Thursday, February 29th. StockNews.com raised Editas Medicine from a "sell" rating to a "hold" rating in a research report on Friday, March 1st. Finally, Barclays lifted their target price on Editas Medicine from $10.00 to $11.00 and gave the company an "equal weight" rating in a research report on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $15.00.

Editas Medicine Stock Performance

NASDAQ EDIT traded up $0.10 on Friday, reaching $5.32. 1,352,080 shares of the stock traded hands, compared to its average volume of 1,817,097. The company has a fifty day moving average price of $7.52 and a 200-day moving average price of $8.31. The company has a market cap of $437.52 million, a price-to-earnings ratio of -2.60 and a beta of 2.01. Editas Medicine has a 12 month low of $5.11 and a 12 month high of $11.91.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.29. Editas Medicine had a negative return on equity of 42.95% and a negative net margin of 196.12%. The firm had revenue of $60.00 million during the quarter, compared to analyst estimates of $4.84 million. During the same period last year, the company earned ($0.88) EPS. Editas Medicine's quarterly revenue was up 817.4% compared to the same quarter last year.

Institutional Trading of Editas Medicine

Several large investors have recently added to or reduced their stakes in the company. Clear Street Markets LLC purchased a new position in Editas Medicine during the third quarter valued at approximately $44,000. Russell Investments Group Ltd. increased its holdings in shares of Editas Medicine by 401.9% during the 4th quarter. Russell Investments Group Ltd. now owns 5,190 shares of the company's stock valued at $53,000 after purchasing an additional 4,156 shares in the last quarter. Amalgamated Bank lifted its stake in shares of Editas Medicine by 18.0% in the 3rd quarter. Amalgamated Bank now owns 8,023 shares of the company's stock valued at $63,000 after purchasing an additional 1,226 shares during the period. Independent Advisor Alliance acquired a new position in shares of Editas Medicine in the 3rd quarter valued at $81,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Editas Medicine by 351.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,450 shares of the company's stock worth $96,000 after buying an additional 7,355 shares in the last quarter. Hedge funds and other institutional investors own 71.90% of the company's stock.

Insider Buying and Selling

In related news, SVP Baisong Mei sold 20,327 shares of the business's stock in a transaction on Monday, March 4th. The stock was sold at an average price of $9.42, for a total transaction of $191,480.34. Following the transaction, the senior vice president now directly owns 141,543 shares in the company, valued at approximately $1,333,335.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Editas Medicine news, CEO Gilmore Neil O'neill sold 77,824 shares of the business's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $9.42, for a total transaction of $733,102.08. Following the sale, the chief executive officer now owns 327,470 shares in the company, valued at approximately $3,084,767.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Baisong Mei sold 20,327 shares of the business's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $9.42, for a total value of $191,480.34. Following the sale, the senior vice president now owns 141,543 shares in the company, valued at approximately $1,333,335.06. The disclosure for this sale can be found here. 1.90% of the stock is owned by company insiders.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.